CVS Health Deferred Revenue decreased by 4.9% to $58.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 66.7%, from $174.00M to $58.00M. Over 4 years (FY 2020 to FY 2024), Deferred Revenue shows an upward trend with a 19.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong sales of subscription-based services or bundled offerings, providing a predictable pipeline for future revenue recognition.
Represents cash payments received from customers in advance of the company fulfilling its performance obligations, speci...
High-growth software and services companies typically maintain larger deferred revenue balances relative to pure hardware manufacturers.
deferred_revenue_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $79.00M | $78.00M | $87.00M | $80.00M | $80.00M | $74.00M | $71.00M | $136.00M | $161.00M | $167.00M | $149.00M | $117.00M | $128.00M | $174.00M | $144.00M | $65.00M | $61.00M | $58.00M |
| QoQ Change | — | -1.3% | +11.5% | -8.0% | +0.0% | -7.5% | -4.1% | +91.5% | +18.4% | +3.7% | -10.8% | -21.5% | +9.4% | +35.9% | -17.2% | -54.9% | -6.2% | -4.9% |
| YoY Change | — | — | — | — | +1.3% | -5.1% | -18.4% | +70.0% | +101.3% | +125.7% | +109.9% | -14.0% | -20.5% | +4.2% | -3.4% | -44.4% | -52.3% | -66.7% |